RESUMEN
BACKGROUND: Potassium-channels in the carotid body and the brainstem are important regulators of ventilation. The BKCa-channel contains response elements for CO, O2, and CO2. Its block increases carotid body signalling, phrenic nerve activity, and respiratory drive. GAL-021, a new BKCa-channel blocker, increases minute ventilation in rats and non-human primates. This study assessed the single-dose safety, tolerability, pharmacokinetics (PKs), and pharmacodynamics (PDs) of GAL-021 in healthy volunteers. METHODS: Thirty subjects participated in a nine-period, randomized, double-blinded, placebo-controlled, crossover, ascending dose, first-in-human study with i.v. infusions of 0.1-0.96 mg kg(-1) h(-1) for 1 h and intermediate doses up to 4 h. RESULTS: Adverse event rates were generally similar among dose levels and between placebo- and GAL-021-treated subjects. At higher GAL-021 doses, a mild/moderate burning sensation at the infusion site occurred during the infusion. No clinically significant changes in vital signs or clinical chemistries were noted. Minute ventilation increased (AUE0-1 h ≈ 16%, P<0.05) and end-tidal carbon dioxide ([Formula: see text]) decreased (AUE0-1 h ≈ 6%, P<0.05) during the first hour at 0.96 mg kg(-1) h(-1) with 1/2-maximal [Formula: see text] and [Formula: see text]-change occurring by 7.5 min. Drug concentration rose rapidly during the infusion and decreased rapidly initially (distribution t1/2 of 30 min) and then more slowly (terminal t1/2 of 5.6 h). CONCLUSIONS: GAL-021 was safe and generally well tolerated with adverse events comparable with placebo except for an infusion site burning sensation. GAL-021 stimulated ventilation at the highest doses suggesting that greater infusion rates may be required for maximum PD effects. GAL-021 had PK characteristics consistent with an acute care medication.
Asunto(s)
Subunidades alfa de los Canales de Potasio de Gran Conductancia Activados por Calcio/antagonistas & inhibidores , Bloqueadores de los Canales de Potasio/farmacología , Triazinas/farmacología , Adulto , Dióxido de Carbono/sangre , Estudios Cruzados , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Femenino , Humanos , Infusiones Intravenosas , Masculino , Bloqueadores de los Canales de Potasio/efectos adversos , Bloqueadores de los Canales de Potasio/farmacocinética , Mecánica Respiratoria/efectos de los fármacos , Triazinas/efectos adversos , Triazinas/farmacocinética , Adulto JovenRESUMEN
Although the mu opioid receptor is the primary target of marketed opioid analgesics, several studies suggest the advantageous effect of combinations of mu and delta opioids. The novel compound RWJ-394674 [N,N-diethyl-4-[(8-phenethyl-8-azabicyclo]3.2.1]oct-3-ylidene)-phenylmethyl]-benzamide]; bound with high affinity to the delta opioid receptor (0.2 nM) and with weaker affinity to the mu opioid receptor (72 nM). 5'-O-(3-[(35)S]-thio)triphosphate binding assay demonstrated its delta agonist function. Surprisingly given this pharmacologic profile, RWJ-394674 exhibited potent oral antinociception (ED(50) = 10.5 micromol/kg or 5 mg/kg) in the mouse hot-plate (48 degrees C) test and produced a moderate Straub tail. Antagonist studies in the more stringent 55 degrees C hot-plate test demonstrated the antinociception produced by RWJ-394674 to be sensitive to the nonselective opioid antagonist naloxone as well as to the delta- and mu-selective antagonists, naltrindole and beta-funaltrexamine, respectively. In vitro studies demonstrated that RWJ-394674 was metabolized by hepatic microsomes to its N-desethyl analog, RWJ-413216 [N-ethyl-4-[(8-phenethyl-8-azabicyclo[3.2.1]oct-3-ylidene)-phenylmethyl]-benzamide], which, in contrast to RWJ-394674, had a high affinity for the mu rather than the delta opioid receptor and was an agonist at both. Pharmacokinetic studies in the rat revealed that oral administration of RWJ-394674 rapidly gave rise to detectable plasma levels of RWJ-413216, which reached levels equivalent to those of RWJ-394674 by 1 h. RWJ-413216 itself demonstrated a potent oral antinociceptive effect. Thus, RWJ-394674 is a delta opioid receptor agonist that appears to augment its antinociceptive effect through biotransformation to a novel mu opioid receptor-selective agonist.
Asunto(s)
Analgésicos Opioides/metabolismo , Analgésicos Opioides/farmacología , Compuestos Bicíclicos Heterocíclicos con Puentes/farmacología , Receptores Opioides delta/agonistas , Receptores Opioides mu/agonistas , Administración Oral , Animales , Compuestos Bicíclicos Heterocíclicos con Puentes/metabolismo , Femenino , Masculino , Ratones , Microsomas Hepáticos/metabolismo , Ratas , Ratas Sprague-Dawley , Ratas WistarRESUMEN
Terminal alkynes, secondary amines, and aldehydes undergo "solid-phase Mannich condensation". A set of diverse aldehyde inputs was examined. Aliphatic, aralkyl, aryl, and heteroaryl carboxaldehydes give good yields of Mannich adduct of high purity. Benzaldehydes containing electron-donating substituents that decrease the electrophilicity of the carbonyl center, or heteroaryl aldehydes that are similarly deactivated by resonance effects, do not undergo reaction.
Asunto(s)
Aldehídos/química , Aldehídos/síntesis química , Alquinos/síntesis química , Aminas/síntesis química , Benzaldehídos/síntesis química , Benzaldehídos/química , Cromatografía Líquida de Alta Presión , Espectroscopía de Resonancia Magnética , Bases de Mannich/química , Espectrometría de MasasRESUMEN
1,3-Disubstituted-5-aminopyrazoles were prepared based on a lead compound found through high-throughput screening of our corporate compound library in an assay measuring affinity for the human neuropeptide Y5 receptor. The target compounds were prepared by cyclization of alpha-cyanoketones with appropriate hydrazines, followed by reduction and coupling to various sulfonamido-carboxylic acids. Several of these arylpyrazoles (e.g., 19 and 45) displayed high affinity for the human NPY Y5 receptor (<20nM IC(50)s).
Asunto(s)
Pirazoles/química , Pirazoles/metabolismo , Receptores de Neuropéptido Y/metabolismo , Relación Estructura-Actividad , Sulfonamidas/química , Sulfonamidas/metabolismo , Unión Competitiva , Línea Celular , Diseño de Fármacos , Evaluación Preclínica de Medicamentos , Humanos , Concentración 50 Inhibidora , Pirazoles/farmacología , Receptores de Neuropéptido Y/efectos de los fármacos , Sulfonamidas/farmacologíaRESUMEN
Alpha-(3-Pyridylmethyl)-beta-aminotetralins were acylated with amino-piperidinyl and-pyrrolidinyl acetic acids, and with (aminomethyl)cyclohexanecarboxylic acid. Reaction with acyl chlorides, chloroformates, and isocyanates gave amides 8e, carbamates 9, and ureas 10, which bound to the Y5 receptor with nanomolar affinity. Congeners 11a and 11d containing a terminal benzimidazolone group were shown to be functional Y5 antagonists.
Asunto(s)
2-Naftilamina/análogos & derivados , Piridinas/química , Piridinas/farmacología , Receptores de Neuropéptido Y/antagonistas & inhibidores , 2-Naftilamina/química , 2-Naftilamina/farmacología , Acilación , HumanosRESUMEN
[3a,4,5,9b-Tetrahydro-1H-benzo[e]indol-2-yl]amines were prepared via reductive amination and concomitant cyclization of alpha-cyanomethyl-beta-aminotetralins. N-acylation with omega-sulfonamido-carboxylic acids and subsequent reduction afforded a series of N-(sulfonamido)alkyl[tetrahydro-1H-benzo[e]indol-2-yl]amines, which bound to the human neuropeptide Y Y5 receptor with nanomolar affinity.
Asunto(s)
Indoles/farmacología , Receptores de Neuropéptido Y/antagonistas & inhibidores , Cristalografía por Rayos X , Humanos , Indoles/síntesis química , Indoles/química , Estructura MolecularAsunto(s)
Receptores de Neuropéptido Y/antagonistas & inhibidores , Sulfonamidas/síntesis química , Tetrahidronaftalenos/síntesis química , Línea Celular , Humanos , Ensayo de Unión Radioligante , Relación Estructura-Actividad , Sulfonamidas/química , Sulfonamidas/farmacología , Tetrahidronaftalenos/química , Tetrahidronaftalenos/metabolismo , TransfecciónRESUMEN
Solid-phase organic synthesis, particularly when used in conjunction with combinatorial techniques, is emerging as a revolutionary technology in chemistry. Multi-component reaction systems are particularly valued because several elements of diversity can be introduced in a single transformation thereby expanding the diversity of compound libraries. A variety of multi-component reactions have been successfully adapted for solid-phase technology as described in this review.
Asunto(s)
Química Orgánica/métodos , Tecnología Farmacéutica/tendencias , CiclizaciónRESUMEN
Biapenem is an injectable carbapenem antibiotic with activity against a broad spectrum of bacteria [155679]. It has been submitted for marketing approval in Japan by Lederle Japan, a joint venture between Cyanamid and Takeda. Biapenem is in phase III trials in Germany, South Africa, Spain, Australia and New Zealand for skin infections, and phase I trials in the UK and the US.
RESUMEN
Two new series of dual-action antibacterial agents were synthesized in which penems and carbapenems were linked at the 2'-position to quinolones through either an ester or a carbamate moiety. Potent, broad-spectrum antibacterial activity was observed for both classes of compounds, indicative of a dual-mode of action.